S&P 500   5,046.47 (+0.48%)
DOW   38,008.03 (+0.67%)
QQQ   427.70 (+0.44%)
AAPL   168.13 (+0.08%)
MSFT   411.13 (-0.17%)
META   511.45 (+3.50%)
GOOGL   156.28 (+0.52%)
AMZN   182.24 (+0.53%)
TSLA   151.42 (-2.59%)
NVDA   855.56 (+1.81%)
AMD   155.91 (+1.23%)
NIO   4.05 (+3.58%)
BABA   69.42 (+0.87%)
T   16.17 (+0.31%)
F   12.13 (+0.75%)
MU   115.18 (-0.99%)
GE   156.71 (+0.67%)
CGC   7.83 (+20.65%)
DIS   114.03 (+0.97%)
AMC   2.92 (-2.01%)
PFE   25.38 (-0.16%)
PYPL   62.83 (-0.68%)
XOM   118.90 (+0.23%)
S&P 500   5,046.47 (+0.48%)
DOW   38,008.03 (+0.67%)
QQQ   427.70 (+0.44%)
AAPL   168.13 (+0.08%)
MSFT   411.13 (-0.17%)
META   511.45 (+3.50%)
GOOGL   156.28 (+0.52%)
AMZN   182.24 (+0.53%)
TSLA   151.42 (-2.59%)
NVDA   855.56 (+1.81%)
AMD   155.91 (+1.23%)
NIO   4.05 (+3.58%)
BABA   69.42 (+0.87%)
T   16.17 (+0.31%)
F   12.13 (+0.75%)
MU   115.18 (-0.99%)
GE   156.71 (+0.67%)
CGC   7.83 (+20.65%)
DIS   114.03 (+0.97%)
AMC   2.92 (-2.01%)
PFE   25.38 (-0.16%)
PYPL   62.83 (-0.68%)
XOM   118.90 (+0.23%)
S&P 500   5,046.47 (+0.48%)
DOW   38,008.03 (+0.67%)
QQQ   427.70 (+0.44%)
AAPL   168.13 (+0.08%)
MSFT   411.13 (-0.17%)
META   511.45 (+3.50%)
GOOGL   156.28 (+0.52%)
AMZN   182.24 (+0.53%)
TSLA   151.42 (-2.59%)
NVDA   855.56 (+1.81%)
AMD   155.91 (+1.23%)
NIO   4.05 (+3.58%)
BABA   69.42 (+0.87%)
T   16.17 (+0.31%)
F   12.13 (+0.75%)
MU   115.18 (-0.99%)
GE   156.71 (+0.67%)
CGC   7.83 (+20.65%)
DIS   114.03 (+0.97%)
AMC   2.92 (-2.01%)
PFE   25.38 (-0.16%)
PYPL   62.83 (-0.68%)
XOM   118.90 (+0.23%)
S&P 500   5,046.47 (+0.48%)
DOW   38,008.03 (+0.67%)
QQQ   427.70 (+0.44%)
AAPL   168.13 (+0.08%)
MSFT   411.13 (-0.17%)
META   511.45 (+3.50%)
GOOGL   156.28 (+0.52%)
AMZN   182.24 (+0.53%)
TSLA   151.42 (-2.59%)
NVDA   855.56 (+1.81%)
AMD   155.91 (+1.23%)
NIO   4.05 (+3.58%)
BABA   69.42 (+0.87%)
T   16.17 (+0.31%)
F   12.13 (+0.75%)
MU   115.18 (-0.99%)
GE   156.71 (+0.67%)
CGC   7.83 (+20.65%)
DIS   114.03 (+0.97%)
AMC   2.92 (-2.01%)
PFE   25.38 (-0.16%)
PYPL   62.83 (-0.68%)
XOM   118.90 (+0.23%)

15 Healthcare Stocks that Analysts Love in a Post-Pandemic World - 1 of 15

 
 

Novo Nordisk A/S (NYSE:NVO)

Consensus Rating
Moderate Buy
Rating Score
2.8
Ratings Breakdown
6 Buy Ratings, 2 Hold Ratings, 0 Sell Ratings.
Consensus Price Target
$133.60 (8.3% Upside)

About Novo Nordisk A/S

Novo Nordisk A/S logoNovo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. Read More 
 

Recent Analyst Ratings

DateBrokerageActionRatingPrice TargetDetails
4/18/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
4/12/2024BMO Capital MarketsInitiated CoverageOutperform$163.00
4/1/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
3/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$160.00
2/20/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00
2/14/2024Cantor FitzgeraldReiterated RatingOverweight ➝ Overweight$140.00
2/1/2024Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$120.00 ➝ $140.00
1/23/2024Morgan StanleyInitiated CoverageOverweight$120.00
1/16/2024UBS GroupInitiated CoverageNeutral
1/12/2024Cantor FitzgeraldReiterated RatingOverweight
 

Could Bitcoin Literally FORCE This Crypto To Rocket Up? (Ad)

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.